589 related articles for article (PubMed ID: 24975932)
1. Safety of antipsychotic drugs: focus on therapeutic and adverse effects.
Werner FM; Coveñas R
Expert Opin Drug Saf; 2014 Aug; 13(8):1031-42. PubMed ID: 24975932
[TBL] [Abstract][Full Text] [Related]
2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
3. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
4. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
Bishara D; Taylor D
Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
[TBL] [Abstract][Full Text] [Related]
5. Schizophrenia: The drug deadlock.
Abbott A
Nature; 2010 Nov; 468(7321):158-9. PubMed ID: 21068804
[No Abstract] [Full Text] [Related]
6. Clozapine for the treatment of schizophrenia.
Fakra E; Azorin JM
Expert Opin Pharmacother; 2012 Sep; 13(13):1923-35. PubMed ID: 22803789
[TBL] [Abstract][Full Text] [Related]
7. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
[TBL] [Abstract][Full Text] [Related]
8. A model of anticholinergic activity of atypical antipsychotic medications.
Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
[TBL] [Abstract][Full Text] [Related]
9. A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics.
Lee ES; Vidal C; Findling RL
J Child Adolesc Psychopharmacol; 2018 Nov; 28(9):582-605. PubMed ID: 30312108
[TBL] [Abstract][Full Text] [Related]
10. [Antipsychotic Treatment of the Adult Patient in the Acute Phase of Schizophrenia].
Bohórquez Peñaranda A; Gómez Restrepo C; García Valencia J; Jaramillo González LE; de la Hoz AM; Arenas Á; Tamayo Martínez N
Rev Colomb Psiquiatr; 2014; 44 Suppl 1():13-28. PubMed ID: 26576459
[TBL] [Abstract][Full Text] [Related]
11. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
13. [Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].
Danilov DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):48-55. PubMed ID: 20517226
[TBL] [Abstract][Full Text] [Related]
14. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; Jones PB
Schizophr Bull; 2006 Oct; 32(4):715-23. PubMed ID: 16540702
[TBL] [Abstract][Full Text] [Related]
16. New antipsychotic medications: what advantages do they offer?
Citrome L
Postgrad Med; 1997 Feb; 101(2):207-10, 213-4. PubMed ID: 9046936
[TBL] [Abstract][Full Text] [Related]
17. [Current pharmacotherapy of schizophrenia].
Bitter I
Orv Hetil; 2004 Jan; 145(3):105-9. PubMed ID: 15027331
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
[TBL] [Abstract][Full Text] [Related]
20. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]